Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries InFlectis BioScience awarded $650K grant from the National Multiple Sclerosis Society to advance IFB-048 preclinical development in Multiple Sclerosis; Research to be Performed by Prof. Popko of Northwestern University By: Newsfile April 30, 2024 at 06:45 AM EDT Nantes, France--(Newsfile Corp. - April 30, 2024) - InFlectis BioScience, a pioneer in developing first-in-class therapies for neuromuscular diseases, announces that it has been awarded a $649,601 grant from the National MS Society's commercial research initiative Fast Forward to advance IFB-048 preclinical development in Multiple Sclerosis (MS). To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: InFlectis Bioscience has been awarded a $650K grant from the National Multiple Sclerosis Society's commercial research initiative Fast Forward to demonstrate preclinical efficacy of its lead MS candidate, IFB-048. IFB-048 is a part of a new class of compounds called ISR modulators, which aim to protect the cells that support and repair neurons damaged by MS and other neurological and autoimmune conditions. IFB-048 parent drug has demonstrated potential to protect oligodendrocytes and/or neurons and to enhance remyelination of neurons in an inflammatory environment in multiple sclerosis preclinical models. Click image above to view full announcement. About InFlectis BioScienceInFlectis is developing first-in-class therapies for neuromuscular diseases and is currently evaluating in clinic an orally available small molecule, named IFB-088 (icerguastat) that has the potential to extend lives or improve the quality-of-life for people suffering from Amyotrophic Lateral Sclerosis (ongoing phase II clinical trial) and demyelinating diseases like Charcot-Marie-Tooth disease (phase 2 ready package). About Northwestern UniversityThe Ken & Ruth Davee Department of Neurology at Northwestern University provides students, residents and fellows with innovative learning opportunities to build their skills, provide evidence-based clinical care through hospital affiliates, and develop new treatments through multidisciplinary research. Based in the Feinberg School of Medicine at Northwestern University and allied with the Northwestern Medicine healthcare system, the program is poised to raise the standard of neurological research and care thanks to close collaboration with research partners as well as colleagues in neurological surgery, neuroradiology and related disciplines.About the National Multiple Sclerosis SocietyThe National MS Society, founded in 1946, is the global leader of a growing movement dedicated to creating a world free of MS. The Society funds cutting-edge research for a cure, drives change through advocacy and provides programs and services to help people affected by MS live their best lives. Connect to learn more and get involved: nationalMSsociety.org, Facebook, X, formerly known as Twitter, Instagram, YouTube or 1-800-344-4867. Contacts: Pierre Miniou pierreminiou@inflectisbioscience.com Distributed by: Reportable, Inc. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/207387 Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
InFlectis BioScience awarded $650K grant from the National Multiple Sclerosis Society to advance IFB-048 preclinical development in Multiple Sclerosis; Research to be Performed by Prof. Popko of Northwestern University By: Newsfile April 30, 2024 at 06:45 AM EDT Nantes, France--(Newsfile Corp. - April 30, 2024) - InFlectis BioScience, a pioneer in developing first-in-class therapies for neuromuscular diseases, announces that it has been awarded a $649,601 grant from the National MS Society's commercial research initiative Fast Forward to advance IFB-048 preclinical development in Multiple Sclerosis (MS). To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: InFlectis Bioscience has been awarded a $650K grant from the National Multiple Sclerosis Society's commercial research initiative Fast Forward to demonstrate preclinical efficacy of its lead MS candidate, IFB-048. IFB-048 is a part of a new class of compounds called ISR modulators, which aim to protect the cells that support and repair neurons damaged by MS and other neurological and autoimmune conditions. IFB-048 parent drug has demonstrated potential to protect oligodendrocytes and/or neurons and to enhance remyelination of neurons in an inflammatory environment in multiple sclerosis preclinical models. Click image above to view full announcement. About InFlectis BioScienceInFlectis is developing first-in-class therapies for neuromuscular diseases and is currently evaluating in clinic an orally available small molecule, named IFB-088 (icerguastat) that has the potential to extend lives or improve the quality-of-life for people suffering from Amyotrophic Lateral Sclerosis (ongoing phase II clinical trial) and demyelinating diseases like Charcot-Marie-Tooth disease (phase 2 ready package). About Northwestern UniversityThe Ken & Ruth Davee Department of Neurology at Northwestern University provides students, residents and fellows with innovative learning opportunities to build their skills, provide evidence-based clinical care through hospital affiliates, and develop new treatments through multidisciplinary research. Based in the Feinberg School of Medicine at Northwestern University and allied with the Northwestern Medicine healthcare system, the program is poised to raise the standard of neurological research and care thanks to close collaboration with research partners as well as colleagues in neurological surgery, neuroradiology and related disciplines.About the National Multiple Sclerosis SocietyThe National MS Society, founded in 1946, is the global leader of a growing movement dedicated to creating a world free of MS. The Society funds cutting-edge research for a cure, drives change through advocacy and provides programs and services to help people affected by MS live their best lives. Connect to learn more and get involved: nationalMSsociety.org, Facebook, X, formerly known as Twitter, Instagram, YouTube or 1-800-344-4867. Contacts: Pierre Miniou pierreminiou@inflectisbioscience.com Distributed by: Reportable, Inc. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/207387
Nantes, France--(Newsfile Corp. - April 30, 2024) - InFlectis BioScience, a pioneer in developing first-in-class therapies for neuromuscular diseases, announces that it has been awarded a $649,601 grant from the National MS Society's commercial research initiative Fast Forward to advance IFB-048 preclinical development in Multiple Sclerosis (MS). To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: InFlectis Bioscience has been awarded a $650K grant from the National Multiple Sclerosis Society's commercial research initiative Fast Forward to demonstrate preclinical efficacy of its lead MS candidate, IFB-048. IFB-048 is a part of a new class of compounds called ISR modulators, which aim to protect the cells that support and repair neurons damaged by MS and other neurological and autoimmune conditions. IFB-048 parent drug has demonstrated potential to protect oligodendrocytes and/or neurons and to enhance remyelination of neurons in an inflammatory environment in multiple sclerosis preclinical models. Click image above to view full announcement. About InFlectis BioScienceInFlectis is developing first-in-class therapies for neuromuscular diseases and is currently evaluating in clinic an orally available small molecule, named IFB-088 (icerguastat) that has the potential to extend lives or improve the quality-of-life for people suffering from Amyotrophic Lateral Sclerosis (ongoing phase II clinical trial) and demyelinating diseases like Charcot-Marie-Tooth disease (phase 2 ready package). About Northwestern UniversityThe Ken & Ruth Davee Department of Neurology at Northwestern University provides students, residents and fellows with innovative learning opportunities to build their skills, provide evidence-based clinical care through hospital affiliates, and develop new treatments through multidisciplinary research. Based in the Feinberg School of Medicine at Northwestern University and allied with the Northwestern Medicine healthcare system, the program is poised to raise the standard of neurological research and care thanks to close collaboration with research partners as well as colleagues in neurological surgery, neuroradiology and related disciplines.About the National Multiple Sclerosis SocietyThe National MS Society, founded in 1946, is the global leader of a growing movement dedicated to creating a world free of MS. The Society funds cutting-edge research for a cure, drives change through advocacy and provides programs and services to help people affected by MS live their best lives. Connect to learn more and get involved: nationalMSsociety.org, Facebook, X, formerly known as Twitter, Instagram, YouTube or 1-800-344-4867. Contacts: Pierre Miniou pierreminiou@inflectisbioscience.com Distributed by: Reportable, Inc. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/207387